Drägerwerk AG & Co. KGaA (ETR:DRW3)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.53B |
| Revenue (ttm) | 3.48B |
| Net Income (ttm) | 139.50M |
| Shares Out | 18.76M |
| EPS (ttm) | 7.44 |
| PE Ratio | 12.41 |
| Forward PE | 11.07 |
| Dividend | 2.27 (2.44%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 15,483 |
| Average Volume | 20,757 |
| Open | 93.40 |
| Previous Close | 93.10 |
| Day's Range | 91.50 - 93.60 |
| 52-Week Range | 58.20 - 99.40 |
| Beta | 0.61 |
| RSI | 48.12 |
| Earnings Date | Apr 30, 2026 |
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departmen... [Read more]
Financial Performance
In 2025, Drägerwerk AG & Co. KGaA's revenue was 3.48 billion, an increase of 3.29% compared to the previous year's 3.37 billion. Earnings were 139.50 million, an increase of 12.13%.
Financial StatementsNews
Drägerwerk Q1 2026 Earnings Soar Beyond Expectations
Preliminary Q1 2026 figures point to solid top-line growth, stronger profitability and robust order intake, while the full-year outlook remains unchanged.
EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 20...
Drägerwerk Q1 2026: Earnings Significantly Up from Last Year!
Dräger starts 2026 with solid momentum: rising sales, stronger margins and robust order intake signal a year of profitable, broad-based growth ahead.
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year 16-Apr-2026 / ...
Drägerwerk AG & Co. KGaA Transcript: German Select VII Conference
The company reported record sales and margin growth in 2025, driven by strong operational performance and innovation in open medical ecosystems. Defense and Safety segments are set for significant expansion, while margin improvement will rely on top-line growth, pricing, and cost control.
Drägerwerk AG & Co: Online-Präsentation German Select 7 Conference am 14.04.2026
Drägerwerk AG & Co. KGaA: Online-Präsentation German Select 7 Conference am 14.04.2026
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q4 2025
Record net sales and EBIT were achieved in 2025, with both divisions and all regions contributing to growth. Despite significant tariff and currency headwinds, profitability improved, and strong cash flow supported higher dividends and reduced debt.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q3 2025
Strong order intake and sales growth drove robust earnings in the first nine months of 2025, with both Medical and Safety divisions contributing. Guidance was raised to the upper end of the range, though FX and regional headwinds remain risks.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q2 2025
H1 2025 saw stable net sales and strong order intake, but EBIT declined due to the absence of prior year one-offs and currency/tariff headwinds. Guidance for 2025 is confirmed, with management confident in margin improvement despite ongoing challenges.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q1 2025
Q1 2025 saw robust order intake and improved cash flow, with the safety division outperforming medical. EBIT and margins declined year-over-year due to higher expenses, but annual guidance is confirmed. Currency volatility and U.S. tariffs present ongoing risks.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q4 2024
Profitability improved in 2024 with EBIT up 17% and stable sales, despite a sharp China decline. Outlook for 2025 is cautious, with 1%-5% sales growth and EBIT margin of 3.5%-6.5% expected. Dividend will rise, and both divisions are set to contribute to growth.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q3 2024
Order intake and net sales remained robust in the first nine months of 2024, with the safety division outperforming the medical division, which was impacted by weak demand in China. One-time gains from asset sales boosted EBIT, and full-year guidance is confirmed with strong Q4 expected.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q2 2024
H1 2024 saw solid performance with EBIT and margins up, driven by strong Safety Division growth and one-off gains, while Medical Division faced headwinds from China. Full-year guidance was confirmed but with a more cautious outlook for China and continued focus on profitability and innovation.